ArticleJournal of neurovirology2015
Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy.
Article in Journal of neurovirology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- MicroRNA biomarkers for JC virus reactivation and progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients: a systematic review.Journal of neurovirology · 2026Review
- From Molecules to Models: miRNAs and Advanced Human Platforms of Neurodegeneration and Repair in Multiple Sclerosis.International journal of molecular sciences · 2025Review
- Exosomal Biomarkers: A Comprehensive Overview of Diagnostic and Prognostic Applications in Malignant and Non-Malignant Disorders.Biomolecules · 2025Review
- Exosome Content-Mediated Signaling Pathways in Multiple Sclerosis.Molecular neurobiology · 2024Review
- Detection of human neurotropic JCPyV DNA sequence in pediatric anaplastic xanthoastrocytoma.Journal of neurovirology · 2023Article
- Article
- Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment.Journal of clinical medicine · 2022Article
- Review
- Detection of polyomavirus microRNA-5p expression in saliva shortly after kidney transplantation.Journal of oral microbiology · 2021Article
- Article
- Biology of Polyomavirus miRNA.Frontiers in microbiology · 2021Review
- Evidence of the Mechanism by Which Polyomaviruses Exploit the Extracellular Vesicle Delivery System during Infection.Viruses · 2020Review
- microRNA and exosome profiling in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2020Review
- Extracellular Vesicles in Neuroinflammation.Frontiers in cell and developmental biology · 2020Review
- Article
- JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.Journal of neurovirology · 2017Article
- A Refined Bead-Free Method to Identify Astrocytic Exosomes in Primary Glial Cultures and Blood Plasma.Frontiers in neuroscience · 2017Article
- Extracellular Vesicles in Brain Tumors and Neurodegenerative Diseases.Frontiers in molecular neuroscience · 2017Review
- Oligonucleotide-based systems: DNA, microRNAs, DNA/RNA aptamers.Essays in biochemistry · 2016Review
- The role of Merkel cell polyomavirus and other human polyomaviruses in emerging hallmarks of cancer.Viruses · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polyomavirus JC (JCPyV) reactivation and development of progressive multifocal leukoencephalopathy is a health concern in multiple sclerosis patients under natalizumab therapy. Here, the JCPyV microRNA-J1-3p and microRNA-J1-5p expressions and genomic variability were investigated in blood and urine samples of multiple sclerosis patients before and under natalizumab therapy and in healthy controls. The two JCPyV microRNAs were detected in the JCPyV-DNA-positive peripheral blood mononuclear cell samples and in the exosomes derived from plasma and urine obtained from JCPyV-DNA-positive and JCPyV-DNA-negative patients. In particular, the increased JCPyV microRNA expression in samples of multiple sclerosis patients under natalizumab therapy was consistent with the high JCPyV-DNA positivity observed in these samples. Moreover, JCPyV microRNA genomic region showed few nucleotide differences in samples obtained from blood and urine of multiple sclerosis patients and healthy controls. Overall, these data suggest a potential role of the JCPyV microRNA expression in counteracting the viral reactivation to maintain JCPyV asymptomatic persistence in the host.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.